玻璃体注射康柏西普联合减压阀植入治疗新生血管性青光眼的初步观察

Intravitrous Conbercept injection combined with Ahmed valve implantation to treat neovascular glaucoma

目的探讨玻璃体内注射康柏西普联合Ahmed青光眼引流阀植入治疗新生血管性青光眼(NVG)的安全性和有效性。方法 14例(18只眼)NVG患者先于玻璃体内注射康柏西普,待虹膜新生血管消退后再行Ahmed青光眼引流阀植入;观察术中并发症及术后虹膜及房角新生血管情况,眼压变化等。随访6个月。结果玻璃体内注药后4~7 d,18只眼新生血管均全部消退。治疗前平均眼压(57.21±6.48)mmHg;减压阀植入术后1个月平均眼压(15.67±3.79)mmHg,术后3个月为(15.22±3.86)mmHg,术后6个月为(15.78±4.44)mmHg。术后1、3、6个月眼压与术前相比差异均有统计学意义(P<0.05),术后1、3、6个月眼压对比差异无统计学意义(P>0.05)。并发症?结论玻璃体内注射康柏西普可使新生血管性青光眼的虹膜新生血管在1周内迅速消退,为青光眼减压阀手术创造良好的条件,且安全有效。

Objective To assess the efficacy and safety of intravitrous Conbercept injection followed by Ahmed valve implantation in the treatment for neovascular glaucoma （ NVG ）. Methods 14 NVG patients （ n = 18 eyes ） were given intravitrous Conbercept injection prior to the surgery. Once iris neovascularization subsided, Ahmed valve was implanted. We observed intra-and postoperative complications, neovascularization on iris and in anterior chamber, and changes in intraocular pressure （ IOP） for 6 months. Results 4 - 7 days after Conbercept injection, neovascular diminished in all 18 eyes. Average IOP before surgery was 57. 21 ±6.48 mmHg. At 1 month after Ahmed valve implantation, average IOP decreased to 15.78 ±4.44 mmHg. Postoperative IOP was significantly lower when compared to preoperative IOP. Conclusions Intravitrous Conbercept injection could diminish iris neovascular within 1 week, creating a favorable ocular condition for Ahmed valve implantation. It is a safe and effective treatment for NVG patients.